PSMA-Targeting Imaging and Theranostic Agents-Current Status and Future Perspective
| Autor: | Sashi Debnath, Ning Zhou, Mark McLaughlin, Samuel Rice, Anil K. Pillai, Guiyang Hao, Xiankai Sun |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Glutamate Carboxypeptidase II
Male theranostics positron emission tomography QH301-705.5 urologic and male genital diseases Catalysis Inorganic Chemistry prostate-specific membrane antigen prostate-specific antigen Humans Biology (General) Physical and Theoretical Chemistry Precision Medicine QD1-999 Molecular Biology Spectroscopy Organic Chemistry Prostatic Neoplasms General Medicine prostate cancer Computer Science Applications inhibitor Chemistry Positron-Emission Tomography Antigens Surface Radiopharmaceuticals |
| Zdroj: | International Journal of Molecular Sciences, Vol 23, Iss 1158, p 1158 (2022) |
| ISSN: | 1422-0067 |
| Popis: | In the past two decades, extensive efforts have been made to develop agents targeting prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy. To date, represented by two recent approvals of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL by the United States Food and Drug Administration (US-FDA) for positron emission tomography (PET) imaging to identify suspected metastases or recurrence in patients with prostate cancer, PSMA-targeting imaging and theranostic agents derived from small molecule PSMA inhibitors have advanced to clinical practice and trials of prostate cancer. The focus of current development of new PSMA-targeting agents has thus shifted to the improvement of in vivo pharmacokinetics and higher specific binding affinity with the aims to further increase the detection sensitivity and specificity and minimize the toxicity to non-target tissues, particularly the kidneys. The main strategies involve systematic chemical modifications of the linkage between the targeting moiety and imaging/therapy payloads. In addition to a summary of the development history of PSMA-targeting agents, this review provides an overview of current advances and future promise of PSMA-targeted imaging and theranostics with focuses on the structural determinants of the chemical modification towards the next generation of PSMA-targeting agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|